Solid Biosciences’ (SLDB) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a research note released on Friday,Benzinga reports. Chardan Capital currently has a $15.00 price target on the stock.

Other equities analysts have also issued reports about the company. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Wedbush reiterated an “outperform” rating and set a $14.00 price target on shares of Solid Biosciences in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Solid Biosciences in a research note on Friday. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Solid Biosciences Stock Performance

Solid Biosciences stock opened at $7.03 on Friday. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $8.72. The firm’s 50-day simple moving average is $6.43 and its 200 day simple moving average is $5.80. The stock has a market cap of $547.71 million, a PE ratio of -3.48 and a beta of 2.64.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.01. As a group, analysts predict that Solid Biosciences will post -2.84 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Alexander Cumbo sold 80,258 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $516,861.52. Following the transaction, the chief executive officer owned 270,931 shares in the company, valued at approximately $1,744,795.64. This represents a 22.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Tan sold 26,837 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total value of $172,830.28. Following the transaction, the chief financial officer directly owned 108,984 shares of the company’s stock, valued at approximately $701,856.96. This trade represents a 19.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 597,672 shares of company stock valued at $3,816,546 in the last quarter. 13.63% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Solid Biosciences

Large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc increased its holdings in Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after acquiring an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Solid Biosciences by 142.0% during the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after purchasing an additional 5,991 shares during the period. Creative Planning bought a new position in Solid Biosciences during the second quarter worth about $57,000. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in shares of Solid Biosciences by 233.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after purchasing an additional 10,585 shares in the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.